Inserm, service de neurologie Clermont-Ferrand, université Clermont-Auvergne, Neuro-Dol, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
Service de physiologie, explorations fonctionnelles, EA 4391, faculté de médecine, université Paris Est Créteil, 94000 Créteil, France; Hôpital Henri-Mondor, Assistance publique-Hôpitaux de Paris, 94000 Créteil, France.
Rev Neurol (Paris). 2019 Jan-Feb;175(1-2):51-58. doi: 10.1016/j.neurol.2018.09.014. Epub 2018 Oct 12.
The use of medications in chronic neuropathic pain may be limited with regard to efficacy and tolerance. Therefore, non-pharmacological approaches, using electrical stimulation of the cortex has been proposed as an alternative. First, in the early nineties, surgically-implanted epidural motor cortex stimulation (EMCS) was proven to be effective to relieve refractory neuropathic pain. Later, non-invasive stimulation techniques were found to produce similar analgesic effects, at least by means of repetitive transcranial magnetic stimulation (rTMS) targeting the primary motor cortex (M1). Following "high-frequency" rTMS (e.g., stimulation frequency ranging from 5 to 20Hz) delivered to the precentral gyrus (e.g., M1 region), it is possible to obtain an analgesic effect via the modulation of several remote brain regions involved in nociceptive information processing or control. This pain reduction can last for weeks beyond the time of the stimulation, especially if repeated sessions are performed, probably related to processes of long-term synaptic plasticity. Transcranial direct current stimulation (tDCS), another form of transcranial stimulation, using low-intensity electrical currents, generally delivered by a pair of large electrodes, has also shown some efficacy to improve patients with chronic pain syndromes. The mechanism of action of tDCS differs from that of EMCS and rTMS, but the cortical target is the same, which is M1. Although the level of evidence of therapeutic efficacy in the context of neuropathic pain is lower for tDCS than for rTMS, interesting perspectives are opened by using at-home tDCS protocols for long-term management. Now, there is a scientific basis for recommending both EMCS and rTMS of M1 to treat refractory chronic neuropathic pain, but their application in clinical practice remains limited due to practical and regulatory issues.
在慢性神经性疼痛中使用药物可能在疗效和耐受性方面受到限制。因此,人们提出了非药物方法,即利用皮层电刺激作为替代方法。首先,在 90 年代早期,经皮植入的硬膜外运动皮层刺激(EMCS)被证明可有效缓解难治性神经性疼痛。后来,人们发现非侵入性刺激技术至少可以通过针对初级运动皮层(M1)的重复经颅磁刺激(rTMS)产生类似的镇痛效果。在对中央前回(例如 M1 区域)施加“高频”rTMS(例如,刺激频率在 5 至 20Hz 之间)后,可以通过调节涉及疼痛信息处理或控制的几个远程脑区来获得镇痛效果。这种疼痛减轻可以在刺激时间之外持续数周,尤其是如果重复进行刺激,这可能与长期突触可塑性的过程有关。另一种经颅刺激形式——经颅直流电刺激(tDCS),使用低强度电流,通常通过一对大电极传递,也显示出对改善慢性疼痛综合征患者的一些疗效。tDCS 的作用机制与 EMCS 和 rTMS 不同,但皮层靶点是相同的,即 M1。尽管 tDCS 在神经性疼痛背景下的治疗疗效的证据水平低于 rTMS,但使用家庭 tDCS 方案进行长期管理开辟了有趣的前景。现在,有科学依据推荐使用 M1 的 EMCS 和 rTMS 来治疗难治性慢性神经性疼痛,但由于实际和监管问题,其在临床实践中的应用仍然受到限制。
Rev Neurol (Paris). 2018-10-12
Handb Clin Neurol. 2013
Cochrane Database Syst Rev. 2014-4-11
Eur J Phys Rehabil Med. 2022-4
Eur J Neurol. 2016-10
Biomed Eng Online. 2024-1-3
Front Neurosci. 2023-10-19
Brain Sci. 2022-12-16